A single psilocybin dose raised sociability in autism-model mice even when given under anaesthesia.
In Cntnap2-knockout mice the effect was durable; isogenic controls showed no change. Separately, a phase 1 study in 56 healthy adults mapped psilocybin from 0.5 to 4.0 mg, finding dose-proportional psilocin exposure, placebo-comparable adverse events and somnolence as the main signal — a defined subperceptual range.